Needham & Company Starts Intermolecular (IMI) at Buy; A Trail Blazer in Semiconductor Process Technology

Needham & Company initiates coverage on Intermolecular (NASDAQ: IMI) with a Buy. PT $13.00.

Needham analyst says, "We believe Intermolecular offers a way for investors to participate in the growth in semiconductor process development spending. We believe Intermolecular’s high productivity combinatorial (HPC) platform offers customers a compelling solution to significantly accelerate development cycle and time-to-market. Through its unique collaborative development programs (CDPs), Intermolecular is able to monopolize process technology development by collecting high margin, royalty-bearing license revenues. Benefitting from strong traction with multiple leading semiconductor customers, we believe Intermolecular is an ideal name for growth investors looking for strong momentum and good visibility into high margin revenue streams."

For an analyst ratings summary and ratings history on Intermolecular click here. For more ratings news on Intermolecular click here.

Shares of Intermolecular closed at $8.82 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Needham Reiterates Buy Rating on Digimarc (DMRC)
• Coherent (COHR) PT Raised to $420 at Needham